» Articles » PMID: 30187870

[Correlation of Apolipoprotein AI, Apolipoprotein B and Their Ratio with the Severity of Cerebral White Matter Lesions]

Overview
Specialty General Medicine
Date 2018 Sep 7
PMID 30187870
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the correlation of apolipoprotein AI (ApoAI), ApoB, ApoB/ApoAI and the severity of brain white matter lesions (WML).

Methods: A total of 648 patients with WML confirmed by brain magnetic resonance imaging (MRI) were divided into mild WML group (=386) and moderate to severe WML group (=262) according to evaluations with the Fazekas scale. The demographic data, blood biochemical parameters and the levels of ApoAI, ApoB and ApoB/AI ratio were compared between the two groups to identify the risk factors of moderate to severe WML.

Results: Univariate analysis showed that age, gender, hypertension, diabetes, coronary heart disease, previous stroke, homocysteine, HDL-C, ApoAI, and ApoB/AI ratio all differed significantly between the two groups ( < 0.05), but ApoB levels were similar between them ( > 0.05). Multivariate logistic regression analysis revealed that with ApoAI and ApoB/AI ratio as the continuous variables, after adjustment for the compounding factors, ApoB/AI ratio was an independent risk factor (OR=11.456, 95% : 3.622-36.229, < 0.001) and ApoAI was an independent protective factor for moderate to severe WML (OR=0.068, 95% : 0.018-0.262, < 0.001). With the upper quartiles of ApoAI level (1.38 g/L) and ApoB/AI ratio (0.58) as their respective cutoff values, patients with a high ApoAI level and a low ApoB/AI ratio were found to have the lowest incidence of moderate to severe WML ( < 0.001).

Conclusions: An increased ApoB/AI ratio is an independent risk factor and an increased ApoAI level is an independent protective factor for moderate to severe WML.

Citing Articles

Improvement of Total Flavonoids from L. in Rats with Chronic Mountain Sickness through H-NMR Metabonomics.

Maimaiti A, Tao Y, Minmin W, Weiwei M, Wenhui S, Aikemu A Evid Based Complement Alternat Med. 2021; 2021:6695346.

PMID: 34007298 PMC: 8110374. DOI: 10.1155/2021/6695346.

References
1.
Kim M, Ahn C, Kang S, Ha J, Baek H, Park J . Association between Apolipoprotein B/Apolipoprotein A-1 and arterial stiffness in metabolic syndrome. Clin Chim Acta. 2014; 437:115-9. DOI: 10.1016/j.cca.2014.07.005. View

2.
Wardlaw J, Smith E, Biessels G, Cordonnier C, Fazekas F, Frayne R . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013; 12(8):822-38. PMC: 3714437. DOI: 10.1016/S1474-4422(13)70124-8. View

3.
Song F, Poljak A, Crawford J, Kochan N, Wen W, Cameron B . Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One. 2012; 7(6):e34078. PMC: 3372509. DOI: 10.1371/journal.pone.0034078. View

4.
Emoto T, Sawada T, Morimoto N, Tenjin T, Wakimoto T, Ikeda F . The apolipoprotein B/A1 ratio is associated with reactive oxygen metabolites and endothelial dysfunction in statin-treated patients with coronary artery disease. J Atheroscler Thromb. 2013; 20(7):623-9. DOI: 10.5551/jat.16824. View

5.
Murray A, Staff R, Shenkin S, Deary I, Starr J, Whalley L . Brain white matter hyperintensities: relative importance of vascular risk factors in nondemented elderly people. Radiology. 2005; 237(1):251-7. DOI: 10.1148/radiol.2371041496. View